Literature DB >> 23253473

Is there still a role for empiric first-line triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for Helicobacter pylori infection in Singapore? Results of a time trend analysis.

Tiing Leong Ang1, Luokai Wang, Daphne Ang, Priscilla Chiam, Kwong Ming Fock, Eng Kiong Teo.   

Abstract

OBJECTIVE: This study was aimed to assess whether the efficacy of one-week triple therapy comprising of proton pump inhibitor, amoxicillin and clarithromycin (PPI/A/C) on Helicobacter pylori (H. pylori) infection in Singapore has decreased over the duration from 2005 to 2010.
METHODS: The clinical data of H. pylori-positive patients treated with one-week PPI/A/C in 2005 and 2010 were reviewed retrospectively using a registry database. The primary endpoint was the difference in treatment success rate.
RESULTS: A total of 465 patients (n = 174 in 2005 and n = 291 in 2010) were analyzed. In 2010, compared with 2005, the mean age of patients was younger (47 vs 56 years, P < 0.001) and the proportion of foreigners was higher (19.9% vs 5.7%, P < 0.001). The success rate of H. pylori eradication remained similar over the two time periods (90.2% in 2005 vs 88.7% in 2010, P = 0.597). Multinomial logistic regression revealed that mean age, gender, diagnosis and nationality had no impact on the success of H. pylori eradication.
CONCLUSIONS: From 2005 to 2010, there was no significant decrease in the efficacy of one-week PPI/A/C for the treatment of H. pylori infection. This treatment regime remained an effective first-line therapy for H. pylori infection in Singapore.
© 2012 The Authors. Journal of Digestive Diseases © 2012 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23253473     DOI: 10.1111/1751-2980.12024

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  5 in total

1.  Current Paradigm and Future Directions for Treatment of Helicobacter pylori Infection.

Authors:  Jason Ferreira; Steven F Moss
Journal:  Curr Treat Options Gastroenterol       Date:  2014-12

2.  Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial.

Authors:  Ayse Kefeli; Sebahat Basyigit; Abdullah Ozgur Yeniova; Tarık Tayfur Kefeli; Muzaffer Aslan; Ozlem Tanas
Journal:  Bosn J Basic Med Sci       Date:  2016-01-01       Impact factor: 3.363

Review 3.  Helicobacter pylori research: historical insights and future directions.

Authors:  Kwong Ming Fock; David Y Graham; Peter Malfertheiner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-06-11       Impact factor: 46.802

4.  The Association of Age and Antibiotic Resistance of Helicobacter Pylori: A Study in Jiaxing City, Zhejiang Province, China.

Authors:  Zizhong Ji; Feng Han; Fei Meng; Miaoying Tu; Ningmin Yang; Jianzhong Zhang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

Review 5.  Helicobacter pylori Treatment Strategies in Singapore.

Authors:  Tiing Leong Ang; Daphne Ang
Journal:  Gut Liver       Date:  2021-01-15       Impact factor: 4.519

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.